AU2002211862B2 - Methods of inducing cancer cell death and tumor regression - Google Patents

Methods of inducing cancer cell death and tumor regression Download PDF

Info

Publication number
AU2002211862B2
AU2002211862B2 AU2002211862A AU2002211862A AU2002211862B2 AU 2002211862 B2 AU2002211862 B2 AU 2002211862B2 AU 2002211862 A AU2002211862 A AU 2002211862A AU 2002211862 A AU2002211862 A AU 2002211862A AU 2002211862 B2 AU2002211862 B2 AU 2002211862B2
Authority
AU
Australia
Prior art keywords
cancer
sch
treatment
inhibitor
fpt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002211862A
Other languages
English (en)
Other versions
AU2002211862A1 (en
Inventor
George Q. Daley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2002211862A1 publication Critical patent/AU2002211862A1/en
Application granted granted Critical
Publication of AU2002211862B2 publication Critical patent/AU2002211862B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2002211862A 2000-10-05 2001-10-05 Methods of inducing cancer cell death and tumor regression Ceased AU2002211862B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23824000P 2000-10-05 2000-10-05
US60/238,240 2000-10-05
PCT/US2001/042509 WO2002028381A2 (en) 2000-10-05 2001-10-05 Methods of inducing cancer cell death and tumor regression

Publications (2)

Publication Number Publication Date
AU2002211862A1 AU2002211862A1 (en) 2002-06-27
AU2002211862B2 true AU2002211862B2 (en) 2007-03-15

Family

ID=22897049

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2002211862A Ceased AU2002211862B2 (en) 2000-10-05 2001-10-05 Methods of inducing cancer cell death and tumor regression
AU1186202A Pending AU1186202A (en) 2000-10-05 2001-10-05 Methods of inducing cancer cell death and tumor regression

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU1186202A Pending AU1186202A (en) 2000-10-05 2001-10-05 Methods of inducing cancer cell death and tumor regression

Country Status (14)

Country Link
US (1) US6777415B2 (cg-RX-API-DMAC7.html)
EP (1) EP1322334A2 (cg-RX-API-DMAC7.html)
JP (1) JP2004510733A (cg-RX-API-DMAC7.html)
CN (1) CN1479630A (cg-RX-API-DMAC7.html)
AU (2) AU2002211862B2 (cg-RX-API-DMAC7.html)
BR (1) BR0114430A (cg-RX-API-DMAC7.html)
CA (1) CA2424797C (cg-RX-API-DMAC7.html)
HK (1) HK1052870A1 (cg-RX-API-DMAC7.html)
HU (1) HUP0302913A3 (cg-RX-API-DMAC7.html)
MX (1) MXPA03003011A (cg-RX-API-DMAC7.html)
NO (1) NO20031531L (cg-RX-API-DMAC7.html)
NZ (1) NZ524936A (cg-RX-API-DMAC7.html)
WO (1) WO2002028381A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200302523B (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6369138B2 (en) 1997-07-11 2002-04-09 Bridgestone Corporation Processability of silica-filled rubber stocks with reduced hysteresis
US8791081B2 (en) * 1999-08-13 2014-07-29 Case Western Reserve University MGMT inhibitor combination for the treatment of neoplastic disorders
US20020077301A1 (en) * 2000-10-05 2002-06-20 Whitehead Institute For Biomedical Research Effects of combined administration of farnesyl transferase inhibitors and signal transduction inhibitors
US20040126755A1 (en) * 2001-08-29 2004-07-01 Stephan Dietrich A Gene expression based method for distinguishing metastatic from non-metastatic forms of a tumor, and use in designing therapeutic drugs
WO2003047697A2 (en) * 2001-11-30 2003-06-12 Schering Corporation Use of an farsenyl protein tranferase inhibitor in combination with other antineoplastic agents for the manufacture of a medicament against cancer
EP1453513A1 (en) * 2001-12-03 2004-09-08 Schering Corporation Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer
US20050004008A1 (en) * 2002-03-01 2005-01-06 Frackelton A. Raymond SHC proteins as therapeutic targets in proliferative diseases
US7910314B2 (en) * 2002-03-01 2011-03-22 Roger Williams Hospital Shc protein-related methods and compositions for the prognosis of breast, prostate and ovarian cancer
US20050101576A1 (en) * 2003-11-06 2005-05-12 Novacea, Inc. Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes
US7691905B2 (en) * 2002-12-24 2010-04-06 New York University Inhibition of melanogenesis and melanoma metastasis with p-aminobenzoic acid (PABA)
BRPI0416316A (pt) * 2003-11-06 2007-01-09 Schering Corp combinação de um inibidor da farnesil transferase com um agente anti-hormonal para o tratamento de cáncer de mama
US20060205810A1 (en) * 2004-11-24 2006-09-14 Schering Corporation Platinum therapeutic combinations
US20070148660A1 (en) * 2005-06-16 2007-06-28 The Regents Of The University Of California Treatment of maladaptive substance use with H-ras antagonists
JP2009511450A (ja) * 2005-10-07 2009-03-19 ノバルティス アクチエンゲゼルシャフト ニロチニブとファルネシルトランスフェラーゼ阻害剤の組合せ
EP1946117B1 (en) * 2005-11-11 2011-08-24 Roger Williams Hospital P66-shc as predictive marker in cancer treatment
CN102274513B (zh) * 2011-07-06 2013-02-20 南开大学 ERK1/2抑制剂通过刺激巨噬细胞干扰素γ表达抑制肿瘤生长
CN102626416B (zh) * 2012-05-11 2013-04-17 江苏省人民医院 他莫昔芬联合雷帕霉素、人参皂苷Rg3复合物在制备治疗肝癌药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997045412A1 (en) * 1996-05-30 1997-12-04 Merck & Co., Inc. A method of treating cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69120430D1 (de) 1990-12-18 1996-07-25 Wellcome Found Mittel zur verstaerkung der wirkung von antitumoralen mittel und zur widerstandsbekaempfung von vielfachdrogen
US5874442A (en) 1995-12-22 1999-02-23 Schering-Plough Corporation Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease
JP2000504023A (ja) 1996-04-03 2000-04-04 メルク エンド カンパニー インコーポレーテッド 癌治療方法
WO1998057948A1 (en) * 1997-06-17 1998-12-23 Schering Corporation Novel n-substituted urea inhibitors of farnesyl-protein transferase
WO1998057945A1 (en) * 1997-06-17 1998-12-23 Schering Corporation Benzo(5,6)cyclohepta(1,2-b)pyridine derivatives as farnesyl protein transferase inhibitors
US6096757A (en) 1998-12-21 2000-08-01 Schering Corporation Method for treating proliferative diseases
DK1140938T3 (da) * 1999-01-11 2003-12-22 Univ Princeton Højaffinitetsinhibitorer for målvalidering og anvendelser heraf
US6316462B1 (en) * 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
ES2273688T3 (es) * 1999-04-14 2007-05-16 Dana-Farber Cancer Institute, Inc. Procedimiento y composicion para el tratamiento de cancer.
US6465448B1 (en) * 1999-08-13 2002-10-15 Case Western Reserve University Methoxyamine potentiation of temozolomide anti-cancer activity
US7238525B2 (en) * 2000-06-30 2007-07-03 The Regents Of The University Of California Strategy for leukemia therapy
US20020077301A1 (en) * 2000-10-05 2002-06-20 Whitehead Institute For Biomedical Research Effects of combined administration of farnesyl transferase inhibitors and signal transduction inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997045412A1 (en) * 1996-05-30 1997-12-04 Merck & Co., Inc. A method of treating cancer

Also Published As

Publication number Publication date
HUP0302913A2 (hu) 2003-12-29
ZA200302523B (en) 2004-08-24
US6777415B2 (en) 2004-08-17
HUP0302913A3 (en) 2005-05-30
US20020128280A1 (en) 2002-09-12
NO20031531L (no) 2003-06-05
AU1186202A (en) 2002-04-15
WO2002028381A2 (en) 2002-04-11
EP1322334A2 (en) 2003-07-02
CN1479630A (zh) 2004-03-03
BR0114430A (pt) 2004-01-06
NO20031531D0 (no) 2003-04-04
NZ524936A (en) 2005-08-26
CA2424797A1 (en) 2002-04-11
MXPA03003011A (es) 2003-07-14
JP2004510733A (ja) 2004-04-08
CA2424797C (en) 2009-12-29
WO2002028381A3 (en) 2003-03-27
HK1052870A1 (zh) 2003-10-03

Similar Documents

Publication Publication Date Title
AU783177B2 (en) Methods of inducing cancer cell death and tumor regression
US6777415B2 (en) Methods of inducing cancer cell death and tumor regression
US8629135B2 (en) Pharmaceutical compositions comprising RET inhibitors and methods for the treatment of cancer
RU2264217C2 (ru) Синергические способы и композиции для лечения рака
KR20220148847A (ko) 다브라페닙, erk 억제제, 및 shp2 억제제를 포함하는 삼중 약학적 조합물
AU2002211862A1 (en) Methods of inducing cancer cell death and tumor regression
US20020156023A1 (en) Lometrexol combination therapy
JP2016539156A (ja) オーロラキナーゼ阻害剤と抗cd30抗体の併用
US20170226100A1 (en) Aminothiazole compounds
EP1868435A2 (en) Combinations, methods and compositions for treating cancer
SK285584B6 (sk) Použitie 11-(4-piperidylidén)-5H-benzo[5,6]-cyklohepta[1,2- b]pyridínovej zlúčeniny ako inhibítora farnezyl-proteíntransferázy na výrobu liečiva na liečenie proliferačného ochorenia
EP3999065B1 (en) Therapeutic compositions comprising idelalisib and defactinib for treating breast cancers
AU2007334381A1 (en) Compositions and methods for the treatment of cancer
WO2020232390A1 (en) Thiazolidinedione compounds for treatment of drug resistant acute lymphoblastic leukemia
AU2005248948A1 (en) Methods of inducing cancer cell death and tumor regression
Shelly et al. A holistic view on c-Kit in cancer: Structure, signaling, pathophysiology and its inhibitors
CN101198253A (zh) 治疗癌症的组合、方法和组合物

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired